Candeblo plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candeblo plus

Property Description
Active Ingredients Candesartan Cilexetil, Hydrochlorothiazide
Form Oral Tablet
Pharmacological Class Antihypertensive Agent (ARB/Thiazide Diuretic)
Common Use Management of Essential Hypertension
Origin Synthetic Compound

Candeblo plus is a prescription-only fixed-dose combination medication used for the systemic management of high blood pressure, or essential hypertension. It combines two separate active ingredients, an Angiotensin II Receptor Blocker (ARB) and a Thiazide Diuretic, in a single oral tablet. This dual-action approach is clinically recognized for providing effective control over blood pressure that may not be adequately achieved with a single medicine.


What Type of Medicine is Candeblo plus?

Candeblo plus is classified as a systemic cardiovascular agent that works as an antihypertensive agent, meaning its primary purpose is to lower elevated blood pressure, reducing strain on the heart and blood vessels throughout the body. This type of product is used to treat essential hypertension. The medication is an entirely synthetic compound formulated for administration via the oral route, representing a combination strategy that serves as an efficient therapeutic approach.


Composition: Candesartan, a Sartan, and a Diuretic

The medicine contains the active ingredients Candesartan Cilexetil and Hydrochlorothiazide (HCTZ), which are formulated into a solid oral tablet with pharmaceutical excipients. Candesartan Cilexetil functions as an Angiotensin II Receptor Blocker (ARB), often referred to as a Sartan, while Hydrochlorothiazide is a Thiazide Diuretic (a "water pill"). This type of combination is a standard treatment option for hypertension, representing its role as a principal cardiovascular medicine.


What is the General Purpose of the Candeblo plus Combination?

The general purpose of the Candeblo plus combination is to provide a more robust and effective control of essential hypertension than single-ingredient therapy. This is achieved by the dual-action principle: Candesartan relaxes the blood vessel walls, and Hydrochlorothiazide reduces excess fluid volume. The effective lowering of blood pressure is a medically validated intervention crucial for long-term cardiovascular health.

Regulatory References

  1. NIH

What side effects are possible with Candeblo plus ?

Possible side effects and safety information

The official safety documentation for Candeblo plus, which combines Candesartan Cilexetil and Hydrochlorothiazide, defines the documented adverse reactions and safety constraints by frequency and affected physiological system. The safety profile is structured to include potential effects, from those commonly reported in clinical trials to rare, serious adverse events.


Documented Adverse Reactions and Frequency

Adverse effects are classified according to regulatory standards:

  • Common Reactions: Frequently observed effects include dizziness, headache, back pain, and symptoms related to the respiratory tract such as upper respiratory tract infection, pharyngitis, and rhinitis.
  • Very Rarely Reported Reactions: Based on post-marketing surveillance, effects identified as very rare include abnormal hepatic function (hepatitis), hematologic conditions such as neutropenia and agranulocytosis, and severe musculoskeletal tissue breakdown (rhabdomyolysis).

Serious Adverse Reactions and System-Specific Patterns

Specific serious safety issues are documented in official labeling, organized by the systems affected:

  • Metabolic and Electrolyte System: The diuretic component can lead to fluid or electrolyte imbalance, including low potassium (hypokalaemia) or low sodium (hyponatraemia). Conversely, the ARB component has been linked to high potassium (hyperkalaemia).
  • Renal Function: The combination has been associated with changes in renal function, including acute renal failure or worsening of existing renal impairment.
  • Angioedema: Rapid swelling of tissues, including the face, lips, and tongue, is a documented serious adverse reaction.
  • Fetal Toxicity: Use during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of injury and death to the developing fetus.

Safety Restrictions and Contextual Considerations

The product is contraindicated in patients with anuria (inability to pass urine), severe hepatic impairment, or severe renal impairment (creatinine clearance le 30 mL/min/1.73 m^2). Dizziness or lightheadedness are noted to be more likely to occur after the first dose, particularly in patients with pre-existing volume depletion.

Overdose and Emergency Response

An overdose of Candeblo plus primarily presents as an exaggerated effect of the medication, leading to signs of profound hemodynamic instability. Documented clinical manifestations often include severely low blood pressure (symptomatic hypotension) and significant changes in heart rhythm, such as either an abnormally fast (tachycardia) or slow (bradycardia) heart rate. Other common presentations involve dizziness, fainting (syncope), and clinical evidence of severe fluid and electrolyte imbalance due to the diuretic component.

Immediate professional medical help must be sought in all suspected overdose situations. Regulatory guidance mandates seeking emergency medical attention or contacting a Poison Help line promptly.

Serious outcomes, though less common, can include acute renal failure (sometimes preceded by low urine output, or oliguria) and potentially life-threatening electrolyte disturbances, notably severe hyponatremia (low sodium levels). In patients with underlying liver disease, the risk of hepatic coma is officially noted.

Treatment for an overdose is strictly symptomatic and supportive, focusing on correcting circulatory collapse and restoring fluid and electrolyte balance. Official documents state there is no specific antidote known. Furthermore, hemodialysis is not effective for removing the Candesartan component. Continuous monitoring of vital signs and serum electrolytes is required during the recovery phase.

Therapeutic Uses of Candeblo plus

What Candeblo Plus Treats: Main Uses and Benefits

Candeblo plus is commonly used for managing essential hypertension (high blood pressure) in adult patients. This medication is considered relevant for patients presenting with conditions characterized by periods of heightened symptoms, specifically when their blood pressure has not been adequately controlled by monotherapy with either component alone.

The medication is applied in addressing the overall systemic burden associated with chronic high blood pressure. The therapeutic focus is relevant for easing symptoms related to heightened physiological activity. The combination helps address symptom clusters related to systemic imbalance by assisting with the reduction of pressure within blood vessels.

This effect provides support that helps ease the overall symptom burden of chronic hypertension. The use of this medication may assist with maintaining functional stability. This supportive relief contributes to easing the physiological strain on the heart and arteries, which may help patients cope more steadily with symptom fluctuations and maintain a sense of stability when symptoms are more noticeable. This is commonly used to help with symptoms that create noticeable physiological strain.


Quick Fact

  • Therapeutic Focus: Relevant for easing symptoms related to heightened physiological activity.
  • Clinical Scenario: Applied across domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms.
  • Patient Benefit: Provides support that helps ease the overall symptom burden.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

The eligibility for using Candeblo plus (candesartan cilexetil/hydrochlorothiazide) is strictly defined by official regulatory guidelines, focusing on specific patient populations and existing medical conditions. It is indicated for use in adult patients whose high blood pressure is not adequately controlled by either component alone.

Populations for Whom Use is Contraindicated

Use of Candeblo plus is absolutely prohibited in several defined patient populations, including:

  • Pregnancy: Women in the second or third trimesters of pregnancy.
  • Organ Function: Patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2) or severe hepatic impairment and/or cholestasis.
  • Other Conditions: Patients with anuria (no urine production), gout, or certain refractory electrolyte imbalances (e.g., refractory hypokalaemia).
  • Hypersensitivity: Patients allergic to the active substances or to any sulfonamide-derived drugs (due to the hydrochlorothiazide component).

Age-Group and Restricted Use

Category Official Regulatory Status
Pediatric Patients Contraindicated in children aged less than 1 year. Safety and efficacy are not established for children and adolescents 1 to 18 years.
Lactation Not recommended for use in nursing women.
First Trimester Not recommended during the first trimester of pregnancy.
Comorbidities Not recommended for primary hyperaldosteronism. Patients with mild to moderate renal or hepatic impairment and those with volume depletion require special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Candeblo plus (Candesartan Cilexetil/Hydrochlorothiazide), focusing on pharmacodynamic effects and altered drug exposure.

Officially Documented Interactions

Type of Interaction Interacting Agent or Category Restriction/Outcome as Stated in Label
Formal Contraindication Aliskiren Co-administration is contraindicated in patients with diabetes mellitus due to the risks of hyperkalemia and renal impairment (dual RAS blockade).
Clearance Modification Lithium Significantly increases serum Lithium concentrations and toxicity by reducing its renal excretion.
Absorption Interference Cholestyramine and Colestipol resins These agents reduce the gastrointestinal absorption of the Hydrochlorothiazide component.
Pharmacodynamic Risk NSAIDs (including COX-2 inhibitors) May attenuate the antihypertensive effect and increase the risk of renal function deterioration, particularly in elderly or volume-depleted patients.
Electrolyte Risk Potassium-sparing diuretics / Potassium supplements Co-administration risks hyperkalemia (elevated serum potassium levels).
PD Toxicity Digoxin (Digitalis) Hypokalemia caused by the diuretic component may exaggerate the cardiac response to Digitalis toxicity.

Timing-Based Constraints

To manage the absorption interference risk, regulatory documents specify that the Hydrochlorothiazide component should be administered at least 4 hours before or 4–6 hours after administration of Cholestyramine or Colestipol resins.

Mechanism of Action

Blocking Receptors to Widen Blood Vessels

One component of Candeblo plus functions as an antagonist to block the Angiotensin II Type 1 ( AT1) receptor . This targeted action suppresses a natural signaling cascade responsible for vasoconstriction (blood vessel narrowing). By preventing this signaling, the drug promotes the relaxation and widening of the peripheral blood vessels, resulting in a reduction of the overall resistance to blood flow in the circulatory system.


Modulating the Kidney's Fluid and Salt Balance

The second component acts as an inhibitor of the Epithelial Sodium Channel ( ENaC) in the kidneys . This mechanistic step decreases the reabsorption of sodium and water back into the bloodstream. The resulting physiological effect is an increase in the excretion of salt and water via urine, which decreases the total fluid volume circulating within the vascular network.


Combined Mechanistic Consequences

The simultaneous modulation of both the Renin-Angiotensin System ( RAAS) and renal fluid transport leads to an additive effect. The two actions are complementary, resulting in the reduction of pressure exerted on the walls of the circulatory system.

Dosage and Administration Information

Official Administration Guidelines

Candeblo plus is an oral fixed-dose combination (FDC) tablet of candesartan cilexetil and hydrochlorothiazide. Its use and dosing are outlined in the official prescribing information.

Standard Labeled Regimen

  • Route of Administration: The medicine is taken orally as a tablet.
  • Dosing Frequency: The standard dose is one tablet once daily, taken at approximately the same time each day.
  • Timing with Meals: The tablet may be administered with or without food.
  • Dosing Principle: The FDC is not for initial therapy. It is used in adult patients whose blood pressure is not adequately controlled by monotherapy with either component alone. The dose is determined by titration of the individual components prior to switching to the combination tablet.

Dosing Adjustments and Restrictions

Patient Population Official Use Instruction (Label-Based)
Pediatric Use Safety and efficacy have not been established; use is restricted to adult patients.
Older Adults No initial dose adjustment is required for elderly patients.
Renal Impairment Contraindicated in patients with severe renal impairment (CrCl le 30 mL/min).
Hepatic Impairment Contraindicated in severe hepatic impairment and/or cholestasis.

Administration Instructions

  • Preparation: The tablet should be swallowed whole with a glass of water.
  • Missed Dose: If a dose is missed, and it is almost time for the next scheduled dose, the patient should skip the missed dose and resume the regular dosing schedule. A double dose must not be taken to compensate for a forgotten dose.

These guidelines define a daily, oral regimen that requires prior stabilization on individual monotherapy components, and they impose specific constraints based on the patient's age and clinical status, such as kidney function.

Recent Clinical Evidence

Evidence for Essential Hypertension

The core research for Candeblo plus was conducted to examine high blood pressure, or essential hypertension, in adults. The main evidence comes from short-term randomized controlled trials (RCTs). These pivotal studies were designed to compare the fixed-dose combination against an inactive substance (placebo) and against the individual active ingredients, Candesartan alone and Hydrochlorothiazide alone.

Research examined the mean change in a patient’s seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) from the start of the study. These pressure measurements are a key focus of clinical evaluation. Studies monitored how these pressure readings evolved, and reported patterns of greater measurement differences when the two active ingredients were observed in combination compared to when each ingredient was evaluated separately.

Duration of Observation and Special Populations

A key part of the research was applied in studies examining patients whose high blood pressure was observed in some studies to be insufficiently controlled by taking only one ingredient. These trials explored the changes in blood pressure measurements upon switching to the fixed-dose combination.

The primary evidence base typically involved follow-up durations that were limited to short periods (8 to 12 weeks). Research has explored blood pressure patterns over somewhat longer periods, such as 9 to 12 months, in observational settings. However, there is limited information for long-term outcomes specific to the fixed-dose combination, and the long-term effects are not fully established based on dedicated, large-scale, controlled trials.

Candeblo plus was evaluated in patient populations that included common cardiovascular risk factors. The research examined outcomes in specific co-occurring conditions such as Type 2 Diabetes Mellitus and Metabolic Syndrome. Data are still emerging for certain subgroups, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Candeblo plus (FAQ)

Q: Is Candeblo plus the same as just taking Candeblo?

No, Candeblo plus is a fixed-dose combination that includes two different active medicines: Candesartan and Hydrochlorothiazide. Candesartan alone is often referred to by the name 'Candeblo'. This combination is typically used for people whose blood pressure is not fully controlled by Candesartan alone.


Q: Are there any foods or drinks to avoid while taking Candeblo plus?

Regulatory documents state that patients should be mindful about using potassium-containing salt substitutes or potassium supplements, and use them only under the direction of a healthcare provider. This caution is noted because the medicine carries a potential risk of increasing potassium levels in the blood.


Q: Is Candeblo plus safe to use in older adults?

Official regulatory documents indicate that the level of the Candesartan component in the blood tends to be higher in elderly patients (ge 65 years old) than in younger adults. Despite this difference, official prescribing information describes that no initial dosage adjustment is typically necessary for elderly patients.


Q: Can women who are planning pregnancy use Candeblo plus?

Use of this medicine is not recommended during the first three months of pregnancy and is strictly contraindicated during the second and third trimesters due to the potential risk of fetal harm. A healthcare provider should be consulted regarding use when planning pregnancy.


Q: Can Candeblo plus be taken at night or in the morning?

The official product information specifies that the standard regimen is one tablet once daily and should be taken at approximately the same time each day. Regulatory documents do not state a specific preference for morning or night dosing, but the importance of taking the medicine at approximately the same time each day is noted.


Q: What does Candeblo plus do to your kidneys?

The medicine is designed to help lower blood pressure by modulating salt and fluid balance in the kidneys, as well as relaxing blood vessels. However, official safety data has noted that changes in kidney function, including instances of acute renal failure, have been reported as adverse effects.


Q: Do you need to get blood tests while taking Candeblo plus?

The diuretic component of the medicine can cause changes to key minerals (electrolytes) and affect kidney function. Due to the potential for these changes, the need for blood tests for monitoring purposes is noted in official information.


Q: Why is the drug called 'plus'?

The term 'plus' in a medication name often indicates that a second active ingredient has been combined with the primary drug in a single tablet. In this case, the second ingredient is the diuretic hydrochlorothiazide, which is combined with the Candesartan component.


Q: What if I take another medicine that also affects my blood pressure with Candeblo plus?

Regulatory warnings state that combining Candeblo plus with other medicines that lower blood pressure, such as certain other heart medicines or pain relievers (NSAIDs), may further lower blood pressure. This interaction may also increase the risk of developing kidney problems.


Q: What are the signs of an allergic reaction to Candeblo plus?

Official safety documents list signs of a serious allergic reaction, which include the rapid swelling of the face, lips, tongue, or throat (known as angioedema). Other signs of a serious reaction can include skin rash and hives. A serious allergic reaction is a medical emergency.


Q: Can I use Candeblo plus if I have diabetes?

Studies and official information indicate that the diuretic component may potentially lead to increased blood sugar (glucose) levels. Due to the potential for increased blood glucose, monitoring may be required for patients with diabetes. The medicine is contraindicated (absolutely prohibited) for diabetic patients taking the medicine Aliskiren.


Q: Is Candeblo plus known to cause skin rashes?

Yes, official safety documents list a skin rash as a documented adverse reaction associated with the medicine. Any new rash while taking the medicine should be brought to the attention of a healthcare provider.


Q: Does Candeblo plus cause weight gain?

While weight gain is not listed as a common side effect in its own right, official safety reports note that unexplained weight gain may be observed. This is sometimes reported as a potential sign of underlying fluid retention or more serious kidney issues.


Q: How long does it take to see an effect from Candeblo plus?

According to the official product information, the maximum blood pressure lowering effect from any given dose can typically be expected within 4 weeks after starting or adjusting that dose. The medicine is intended to be taken consistently as prescribed.


Q: Does Candeblo plus affect your energy levels?

Official reports on side effects indicate that feeling tired (fatigue) is a common adverse reaction associated with this medicine. Persistent or problematic fatigue may be a topic for discussion with a healthcare professional.


Q: Is there a generic version of Candeblo plus available?

Yes, official governmental drug records indicate that the FDA has approved generic versions of this combination medicine. Generic versions contain the same active ingredients and are held to the same quality standards as the original branded product.


Q: Can Candeblo plus cause coughing?

Official safety data indicates that cough is listed as a potential side effect in adverse reaction reports associated with this medicine. The development of a persistent cough may be a topic for discussion with a healthcare provider.


Q: Is it okay to drink alcohol while taking Candeblo plus?

Official labeling states that alcohol may have an additive effect in lowering blood pressure. This interaction can increase the likelihood of experiencing dizziness, lightheadedness, or fainting, especially when taking the medicine.


Q: How long does Candeblo plus stay in your system?

According to clinical pharmacology data, the time it takes for half of the medicine to be eliminated from the body (the elimination half-life) is about 9 hours for the Candesartan component. The Hydrochlorothiazide component's half-life ranges between mathbf5.6 and mathbf14.8 hours.


Q: Are there any known interactions with herbal supplements and Candeblo plus?

There is limited regulatory information in official drug documents concerning specific interactions between this medicine and various herbal supplements. Due to this lack of data, it is important that a healthcare provider is made aware of all herbal remedies and supplements being taken.


Q: Is it normal for Candeblo plus to make me feel tired?

Yes, official reports classify feeling tired (fatigue) as a common adverse reaction associated with the medicine. Experiencing fatigue is not unusual while taking this medication.


Q: What should I do if a side effect of Candeblo plus feels severe?

A severe or bothersome side effect, or a suspected serious allergic reaction, is described in patient information as a situation where contact with a healthcare provider or immediate emergency medical attention may be necessary.


Q: Can Candeblo plus be stopped suddenly?

Official patient guidelines note that the medicine is used for blood pressure management and discontinuation must be guided by a healthcare provider. This medicine should not be stopped suddenly without professional advice.


Q: Can Candeblo plus affect blood sugar levels?

Yes, official safety information indicates that this medicine may increase blood sugar (glucose) levels in some patients. Due to the potential for increased blood sugar, monitoring may be required, particularly for those with known diabetes.


Q: Is Candeblo plus available in different strengths?

Yes, according to official regulatory labeling, the combination of Candesartan and Hydrochlorothiazide is supplied in multiple fixed-dose strengths. This allows for the selection of an appropriate dose combination when switching patients from individual component therapy to the combination tablet.

How should Candeblo plus be stored and disposed of?

Candeblo plus tablets should be stored in their original blister packaging to protect them from moisture and light. Keep the medication in a closed container at room temperature, generally defined as below 30 C or 86 F, and away from excessive heat. It is critical to store this and all medications out of the sight and reach of children and pets.

Do not use Candeblo plus after the expiration date printed on the packaging. When disposing of medicine that is no longer needed or expired, do not discard it in household trash or pour it down a sink or toilet. Proper disposal methods help protect the environment. Consult your pharmacist or healthcare professional for guidance on community take-back programs or other safe disposal procedures for unused or outdated medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candeblo plus  found in:

A-Z Index: